ProPhet is an AI-driven company transforming small molecule drug discovery, with a focus on proteins that are hard to target using competitive methods. The company develops advanced technology to identify potential therapeutics for these challenging targets, addressing a critical need in the pharmaceutical industry. Its innovative approach leverages artificial intelligence and machine learning to speed up and enhance the early stages of drug discovery. By predicting protein dynamics and how they interact with drug candidates, ProPhet can rapidly identify promising molecules. This allows to tackle proteins with limited structural information, opening new possibilities for treating diseases previously considered “undruggable.” ProPhet stands out by combining speed, precision, and scientific rigor. Its AI platform evaluates vast libraries of small molecules, offering faster, more efficient, and cost-effective solutions compared to both traditional and other AI-based methods. By doing so, it helps pharmaceutical companies and researchers explore a broader range of treatments with more accuracy, backed by scientifically interpretable results. Its vision is to revolutionize drug discovery, making it faster and more accessible. ProPhet aims to deliver better solutions to help meet unmet medical needs and improve patient outcomes.